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Abstract: Purpose: To describe 5-fluorouracil (5FU) pharmacokinetics, myelotoxicity and respective co-
variates using a simultaneous nonlinear mixed effect modelling approach. Methods: Thirty patients with
gastrointestinal cancer received 5FU 650 or 1000 mg/m2/day as 5-day continuous venous infusion (14
of whom also received cisplatin 20 mg/m2/day). 5FU and 5-fluoro-5,6-dihydrouracil (5FUH2) plasma
concentrations were described by a pharmacokinetic model using NONMEM. Absolute leukocyte counts
were described by a semi-mechanistic myelosuppression model. Covariate relationships were evaluated
to explain the possible sources of variability in 5FU pharmacokinetics and pharmacodynamics. Results:
Total clearance of 5FU correlated with body surface area (BSA). Population estimate for total clearance
was 249 L/h. Clearances of 5FU and 5FUH2 fractionally changed by 77%/m2 difference from the median
BSA. 5FU central and peripheral volumes of distribution were 5.56 L and 28.5 L, respectively. Estimated
5FUH2 clearance and volume of distribution were 121 L/h and 96.7 L, respectively. Baseline leukocyte
count of 6.86 × 109/L, as well as mean leukocyte transit time of 281 h accounting for time delay between
proliferating and circulating cells, was estimated. The relationship between 5FU plasma concentrations
and absolute leukocyte count was found to be linear. A higher degree of myelosuppression was attributed
to combination therapy (slope = 2.82 L/mg) with cisplatin as compared to 5FU monotherapy (slope
= 1.17 L/mg). Conclusions: BSA should be taken into account for predicting 5FU exposure. Myelo-
suppression was influenced by 5FU exposure and concomitant administration of cisplatin. Keywords:
5-Fluorouracil; Myelosuppression; Pharmacodynamics; Pharmacogenetics; Pharmacokinetics.
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Purpose: To describe 5-fluorouracil (5FU) pharmacokinetics, myelotoxicity and respective covariates using a 2 
simultaneous nonlinear mixed effect modelling approach.  3 
Methods: Thirty patients with gastrointestinal cancer received 5FU 650 or 1000 mg/m²/day as 5-days continuous 4 
venous infusion (14 of whom also received cisplatin 20 mg/m²/day). 5FU and 5-fluoro-5,6-dihydrouracil 5 
(5FUH2) plasma concentrations were described by a pharmacokinetic model using NONMEM. Absolute 6 
leukocyte counts were described by a semi-mechanistic myelosuppression model. Covariate relationships were 7 
evaluated to explain the possible sources of variability in 5FU pharmacokinetics and pharmacodynamics. 8 
Results: Total clearance of 5FU correlated with body surface area (BSA). Population estimate for total clearance 9 
was 249 L/h. Clearances of 5FU and 5FUH2 fractionally changed by 77% per m² difference from the median 10 
BSA. 5FU central and peripheral volumes of distribution were 5.56 L and 28.5 L, respectively. Estimated 5FUH2 11 
clearance and volume of distribution were 121 L/h and 96.7 L, respectively. Baseline leukocyte count of 12 
6.86×109/L, whereas mean leukocyte transit time of 281 h accounting for time delay between proliferating and 13 
circulating cells were estimated. A higher degree of myelosuppression was attributed to combination therapy 14 
(slope=2.82 L/mg) with cisplatin as compared to 5FU monotherapy (slope=1.17 L/mg), where the relationship 15 
between 5FU plasma concentrations and absolute leukocyte count was found to be linear.  16 
Conclusions: BSA should be taken into account for predicting 5FU exposure. Myelosuppression was influenced 17 
by 5FU exposure and concomitant administration of cisplatin. 18 






































































The pyrimidine antimetabolite 5-fluorouracil (5FU) is being used since decades for the treatment of 2 
gastrointestinal solid malignancies [1]. Dose, but also route and schedule of administration have been identified 3 
to influence 5FU pharmacokinetics (PK) and effects [2, 3]. Considerable variations in PK and toxicity are 4 
associated with a given 5FU dosing regimen [4]. Investigations have been carried out evaluating patient’s factors 5 
to predict 5FU exposure, where a relationship between body surface area (BSA) and 5FU clearance (CL5FU) was 6 
reported [3, 5]. CL5FU was found to be lower in females [6] and at older age [5, 7]. Due to saturable hepatic 7 
degradation, 5FU PK is considered to be non-linear in nature [8]. Additionally, elimination of the drug was 8 
reported to be influenced by hepatic metastases [3] and by glomerular filtration rate as measured by creatinine 9 
clearance [6]. 10 
Being a prodrug, 5FU requires enzymatic activation. A small fraction of an administered dose is metabolised into 11 
cytotoxic nucleotides, while most of the drug is degraded to 5-fluoro-5,6-dihydrouracil (5FUH2) mainly by 12 
hepatic dihydropyrimidine dehydrogenase (DPD) [9]. Some rare variants of the highly polymorphic DPD gene 13 
(DPYD) are responsible for complete or partial loss of DPD activity, which is related to increased 5FU toxicity 14 
[10]. Belonging to the class of antimetabolites, 5FU inhibits thymidylate synthase (TS), ultimately leading to the 15 
impairment of DNA synthesis [11]. Polymorphisms in the gene encoding TS influence toxicity and response of 16 
5FU based therapeutic regimens [12]. Methylenetetrahydrofolate reductase (MTHFR) is involved in formation of 17 
the reduced folate cofactor, which is required for the inhibition of TS. Genetic polymorphisms in the gene 18 
encoding MTHFR are associated with altered enzymatic activity, thereby influencing sensitivity towards 5FU 19 
[13]. 20 
5FU is commonly used in combination with other antineoplastic drugs and with radiotherapy. A therapeutic 21 
regimen known as FOLFIRINOX including 5FU, folinic acid, oxaliplatin and irinotecan is frequently employed 22 
for the treatment of colorectal and pancreatic cancer [14]. Another regimen, called de Gramont, includes a 23 
combination of 5FU and leucovorin (folinic acid) and has been reported to possess low toxicity profile, increased 24 




































































recommend drug treatments [16]. Approximately 10%–30% of 5FU treated patients experience severe treatment-1 
related toxicity [17], where myelosuppression and mucositis have been reported as main dose limiting side effects 2 
in 5FU treatment [18]. Continuous infusions exhibit lower myelosuppression with greater efficacy and are 3 
considered superior over the bolus administrations [19]. Furthermore, 5FU has a narrow therapeutic index with 4 
severe toxicities tending to occur with AUC values >25 mg h/L during continuous venous infusion [20]. 5 
Therefore, therapeutic drug monitoring is considered valuable to achieve optimal 5FU exposure with minimal 6 
serious toxicity [21].  7 
Semiphysiological myelosuppression models were developed in both animals and human beings to understand 8 
time course and extent of leukopenia following administration of cytotoxic antineoplastic drugs, thus facilitating 9 
the drug development and therapy [22]. Models incorporating white blood cell (WBC) count over time are 10 
helpful to predict the time (Tnadir) and depth (WBCnadir) of lowest total WBC count and the duration of the 11 
recovery period in order to administer the next cycle of a regimen [23]. Efforts have been made to predict the 12 
time course of myelosuppression by 5FU in rats [24]. Population analysis was carried out for the hematological 13 
toxicity in breast cancer patients treated with combined 5FU, epirubicin and cyclophosphamide regimen [25] but 14 
such a study with 5FU monotherapy is lacking.  15 
The objective of the present study was to describe the PK and associated variability of 5FU and its metabolite by 16 
developing an empirical model. Subsequently, it was aimed to establish the relationship between 5FU exposure 17 
and myelotoxicity through a semi-mechanistic PKPD model. The study was further focused towards the 18 
identification and quantitative description of covariates on 5FU PK and myelotoxicity, especially patient 19 
demographics and genotypes (DPYD, MTHFR, TS).  20 
Methods 21 
Patients and treatment plan 22 
The study was approved by the Ethics Committee of the Medical Faculty of the University of Cologne, Germany 23 




































































international legal stipulations and guidelines in 2002 to 2005 [26, 27]. Sample size was estimated using 1 
WinBiAS (version 7.01, epsilon Verlag, Darmstadt, Germany) considering interindividual variability (IIV) in 2 
5FU pharmacokinetics to be at least 30%. To assess the effect of a covariate on 5FU pharmacokinetics, assuming 3 
a linear coefficient of correlation  = 0.5477 (explaining a fraction of 2 = 0.3 of variability) with a power of 90% 4 
and α = 0.05, n = 30 patients were required. To account for possible dropouts, thirty-three patients with colorectal 5 
or oesophageal cancer were planned to be enrolled in the study after the provision of written informed consent. 6 
Eligibility criteria included age ≥ 18 years; Karnofsky performance status ≥ 70%; life expectancy ≥ 3 months; 7 
adequate haematopoietic, hepatic, and renal function. Exclusion criteria were prior chemotherapy or radiotherapy, 8 
and concomitant drugs (not included in the chemotherapeutic regimen) known to interfere with 5FU PK and/or 9 
pharmacodynamics. The patients with colorectal cancer received 5FU 650 or 1000 mg/m²/day as 24-hours 10 
continuous venous infusion for 5 days, and radiotherapy. The patients with oesophageal cancer additionally 11 
obtained cisplatin 20 mg/m²/day for 5 days before, or together with 5FU administration. Any decision on 12 
treatment was made according to the clinical situation and was not influenced by the study. WBC count was 13 
evaluated once prior to and 1-3 times per week after 5FU administration, but prior to the second cycle starting on 14 
day 28, as the assessment of myelosuppression was aimed to be investigated under the influence of single cycle 15 
of treatment. Only the first cycle was monitored in each participant. Covariate data regarding patient 16 
demographics and essential laboratory values were collected prior to the treatment. 17 
Genotyping 18 
DNA was extracted from peripheral blood using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany). 19 
For DPYD genotyping [28], PCR amplification of all 23 coding exons and exon-intron boundaries of the DPYD 20 
gene was carried out. PCR products were separated on 1.6% agarose gels, visualized with ethidium bromide and 21 
purified using a QIA quick Gel Extraction Kit (Qiagen, Hilden, Germany). Samples were sequenced on an ABI 22 
3100 automated DNA sequencer (Applied Biosystems, Foster City, CA, USA). TS genotyping was carried by 23 
PCR amplification [29] of the TS promoter enhancer region containing the double and triple tandem repeats out 24 
using the following primers: forward 5´AAAAGGCGCGCGGAAGGGGTCCT3´; reverse 25 




































































min) and extension at 72°C for 5 min were carried out following hot start at 94°C for 4 min. The PCR product 1 
was analyzed in a 3% agarose gel. The triple repeat (3R/3R) had a 144 bp PCR product, the double repeat 2 
(2R/2R) a 116 bp product. For MTHFR genotyping [30], the PCR reaction used forward primer 3 
5´TGAAGGAGAAGGTGTCTGCGGGA3´ and reverse primer 5´AGGACGGTGCGCTGAGAGTG3´. 4 
Restriction fragment analysis was carried out using Hinf I (Fermentas, St. Leon-Rot, Germany). The C→T 5 
substitution at nucleotide 667 creates a Hinf I digestion site resulting in two fragments (175 bp and 23 bp) of the 6 
PCR product.  7 
Analysis of 5FU and 5FUH2 plasma concentrations  8 
Analytical grade reagents were purchased from Merck (Darmstadt, Germany). 5FU (Sigma, St. Louis, MO, USA) 9 
was purchased as crystalline form, pure > 95%, 5FUH2 (26.5% pure) was supplied by Syncom (Groningen, The 10 
Netherlands), and 5-chlorouracil (5-CU), the internal standard, was obtained from Arcos Organics (Geel, 11 
Belgium).  12 
Blood samples (4.5 mL each) were withdrawn during the first cycle using Li+-heparinized tubes pre-dose, 36, 48, 13 
and 108 hours after the start of 5FU infusion, at the end of infusion, and 5, 30, 60 and 90 min thereafter. The 14 
samples were immediately placed in an ice water bath and centrifugated at +4°C. Plasma was stored at -80°C 15 
until analysis. 5FU and 5FUH2 in plasma were quantified by reverse-phase HPLC method with UV detection. 16 
Briefly, 0.7 mL of plasma was mixed with 20 µL of 100 µg/mL 5-CU (internal standard) and extracted with 7 mL 17 
of isopropranol/ethyl acetate (5:95, v/v). Samples were mixed and centrifuged (3500 rpm, 10 min) to separate the 18 
organic phase, which was evaporated to dryness. The samples were reconstituted with 100 µL of 50 mM K2HPO4 19 
(pH 4.0), and 40 L were injected into the HPLC system. 5FU and 5FUH2 were separated on an Ultrasphere 20 
ODS C18 column (5 m, 250x4.6 mm, Beckman Coulter, Brea, CA, USA). Elution was performed under gradient 21 
condition as follows: 50 mM K2HPO4 (A) for 17 min, acetonitrile (B) 0-50% over 1 min and maintained at 50% 22 
for 5 min; initial conditions were restored by decreasing B to 0% over 1 min, and the column was equilibrated 23 
with 100% A for 5 min. The chromatographic instrument was a Waters 2690 Separations Module (Waters, 24 




































































carried out at 265, 220 and 270 nm, respectively. Data analysis was performed by the Millennium 2.1 software 1 
(Waters, Milford, MA, USA). The LLOQs were 0.005 and 0.01 µg/mL for 5FU and 5FUH2, respectively. The 2 
5FU and 5FUH2 intra-assay coefficients of variation ranged from 0.34 to 7.15% and from 0.53 to 2.76%, 3 
respectively, while the inter-assay coefficients of variation for a 5-day validation were 0.1–3.4% and 2.3–9.0%, 4 
respectively.  5 
Data analysis 6 
Model development and selection criteria  7 
R (version 3.2.3) was used for data manipulation and exploratory evaluation [31]. Population parameter estimates 8 
were obtained using first order conditional estimation with interaction (FOCE-I) algorithm in NONMEM 7.4.2 9 
(ICON, Development Solutions, Elliot City, MD, USA) [32]. Model development process was aided by Perl-10 
speaks-NONMEM (PsN) toolkit (Version 4.7.0) [33]. IIV in model parameters was estimated assuming a log-11 
normal distribution. Additive, proportional and combined error models were implemented to estimate residual 12 
unexplained variabilities (RUV) for 5FU and 5FUH2. Model selection/rejection was guided by decrease in 13 
objective function value (OFV) which was assumed to be chi-squared distributed (p<0.05, corresponding to a 14 
ΔOFV≥3.84 given a change by one degree of freedom), diagnostic plots, scientific plausibility and precision of 15 
parameter estimates. Precision of population parameter estimates was assessed with the help of a bootstrap 16 
procedure using 1000 sample replicates. 17 
Pharmacokinetic analysis 18 
An empirical compartmental model for 5FU was first developed and then expanded to a combined model 19 
incorporating 5FUH2 data. The drug was presumed to be eliminated from the central compartment where 20 
elimination was tested to follow either a linear behaviour or nonlinear Michaelis-Menten kinetics. The fraction of 21 
5FU converted to 5FUH2 was fixed a priori to 0.85, according to the literature [6]. PK parameters were 22 
estimated based on the absolute dose administered.  23 




































































The PD model was developed according to Friberg et al [24, 34] using simultaneous approach. The model was 1 
driven by 5FU plasma concentrations from the PK model and comprised a compartment of proliferating 2 
leukocytes (rate constant describing the proliferation of cells: kprol), transit compartments representing leukocytes 3 
undergoing maturation (rate constant describing the transfer between transit compartments: ktr) and a 4 
compartment of circulating leukocytes (rate constant describing the rate of exit from the circulating compartment: 5 
kcirc). Parameters were the baseline circulating leukocyte count (Circ0) representing the number of cells prior to 6 
5FU administration, mean transit time (MTT = [n +1] / ktr, where n denotes the number of transit compartments) 7 
and a parameter γ describing a negative feedback of circulating cells on the rate of self‐renewal of the 8 
proliferative cells (feedback = [Circ0 / Circ]γ). The number of parameters to be estimated were minimized by 9 
assuming kprol = ktr = kcirc. 5FU plasma concentrations were assumed to inhibit the proliferation of leukocytes.   10 
The drug effect (Edrug) on proliferating cells was assumed to be driven by individual predicted 5FU plasma 11 
concentrations (Cp) and was incorporated in to the model as kprol × (1 - Edrug). Edrug was either formulated as a 12 
linear model (Edrug = slope × Cp) or a nonlinear model (Edrug  = Emax × Cp / (EC50 + Cp)).    13 
Covariate analysis 14 
Covariates tested in the PK analysis included demographics (age, weight, height, sex, body mass index, lean body 15 
weight, BSA); predose plasma concentrations of alanine aminotransferase (ALT), aspartate aminotransferase 16 
(AST) γ-glutamyltransferase (γ-GT), and albumin; and DPYD, TS, and MTHFR genotypes. The effect of co-17 
medication with cisplatin was tested on slope. Scientific plausibility was the primary basis for covariate pre-18 
selection, while graphical evaluation (residuals and individual PK estimates versus covariates) was performed to 19 
assist the inclusion decision. A comparative analysis was carried out to assess any possible superiority of other 20 
indices representing body mass over the BSA such as BMI, LBW and allometric scaling with body weight.  21 
Simulation design 22 
The effect of concomitant cisplatin administration on leukocyte suppression was evaluated. WBC counts over 23 




































































medication. WBCnadir and Tnadir for the respective regimens were determined to assess the degree of 1 
myelosuppression. 2 
Another simulation scenario aimed towards the comparative assessment of the time course of myelosuppression 3 
theoretically produced by the 5FU component contained in a single cycle of the two standard dosage regimens 4 
used in current clinical practice; to this end, the effects of the other components of the regimens were ignored.  5 
The standard FOLFIRINOX regimen combines oxaliplatin (85 mg/m2 over 2 hours) with folinic acid 6 
(200 mg/m2) followed by irinotecan (180 mg/m2 over 90 min) and 5FU (400 mg/m2 bolus) followed by 7 
2400 mg/m2 5FU over 46 h, all on day 1 and repeated every 2 weeks [14]. The de Gramont regimen is described 8 
as follows: high-dose folinic acid (200 mg/m2) followed by 5FU i.v. bolus (300 mg/m2) and continuous infusion 9 
(300 mg/m2) on days 1, 2, 14 and 15, repeated every 4 weeks. In the absence of toxicity, 5-FU is increased to 400 10 
mg/m2 i.v. bolus and continuous infusion at course 2 and to 500 mg/m2 at course 3 and from course 4 maintained 11 
at 500 mg/m2 [15]. Simulated WBCnadir and Tnadir were observed for treatment with FOLFIRINOX (400 mg/m2 12 
bolus 5FU followed by 2400 mg/m2 5FU over 46 h) and de Gramont (5FU 300 mg/m2 i.v. bolus followed by 300 13 
mg/m2 continuous infusion over 24 hrs) regimens. 14 
Results 15 
Patient characteristics 16 
Thirty-three patients were included in the study; of these, 3 patients dropped out prior to the first administration 17 
of 5-FU. The remaining 30 patients who all completed the study comprised 5 women and 25 men with an age 18 
ranging between 37 and 73 years. 16 patients with colorectal cancer were administered 5FU only, while 14 with 19 
oesophageal cancer were treated with the combination of 5FU with cisplatin. Patient demographics, primary 20 
tumor location, pre-treatment values of haematology and clinical chemistry parameters are summarized in table 1.  21 
Genotypes 22 
Analysis of the DPYD gene revealed the presence of 6 polymorphisms in 22 of 30 patients. Eight patients had 23 




































































causing extremely reduced or absent DPD activity, such as exon 14 (DPYD*2A) G>A skipping mutation [35] 1 
were found in the study population. The six DPYD polymorphisms detected in our study were considered to 2 
result in either normal (i.e. 1236G>A [36]) or partially reduced enzyme activity [37]. 3 
With regard to the TS genotype, 5 (16.7%) patients were homozygous for the triple repeat (3R/3R), 19 (63.3%) 4 
were heterozygous (2R/3R), and 6 (20%) were homozygous (2R/2R) for the double repeat variant within the TS 5 
promoter region. As for C677T MTHFR genotype, 13 of 30 patients (43.3%) were CC (wild-type), 12 (40%) - CT 6 
(heterozygous mutant), and 5 (16.7%) - TT (homozygous mutant).  7 
Pharmacokinetic model 8 
199 and 251 quantifiable plasma concentrations of 5FU and 5FUH2, respectively, were part of the 9 
pharmacokinetic model development. Fig. 1 provides a schematic representation of the PKPD model. A two-10 
compartment model with linear elimination (∆OFV of 210 compared to one-compartment model) best described 11 
the 5FU concentration-time data, and a one-compartment model was appropriate for the 5FUH2 data. IIV in the 12 
combined model was included for CL5FU, CL5FUH2, VC,5FU and VC,5FUH2. IIV on VP,5FU was removed because of a 13 
high shrinkage value, while IIV on intercompartmental clearance (Q) was negligible and hence removed from the 14 
final model. A proportional error model was appropriate to model RUV for both 5FU and 5FUH2. Visual 15 
predictive checks (VPCs) indicated an adequate prediction of the 5FU and 5FUH2 concentrations by the model 16 
(fig. 2). Population pharmacokinetic parameter estimates are presented in table 3.  17 
Pharmacodynamic model 18 
In total, 135 observations for total WBC count were available for 29 patients. None of the patients received a 19 
WBC count-modifying drug (e.g. filgrastim). The semi-mechanistic model with three transit compartments 20 
adequately described the time course of myelosuppression (fig. 2). A linear model was preferred over an Emax 21 
model, as the Emax model did not provide any additional goodness-of-fit to describe the PK / PD relationship. The 22 
estimated parameter γ for the feedback mechanism was inconsistent across different runs and was therefore fixed 23 




































































significant impact on the model fit (∆OFV=3.68). IIV on MTT and slope were not kept in the final model as they 1 
displayed high shrinkage and provided no further improvement with ∆OFV values of 1.32 and 0.09, respectively. 2 
A proportional error model was found adequate to model RUV. Pharmacodynamic parameter estimates are 3 
presented in table 3. 4 
Covariate relationships 5 
Estimated IIV in CL5FU in the covariate-free model was 32.8% (CV), whereas a 9% reduction in IIV resulted with 6 
the inclusion of BSA as covariate. Scaling with BSA (∆OFV=10.1) was found superior to that with LBW 7 
(∆OFV=6.4), BMI (∆OFV=4.3) and body weight (∆OFV=5.0). CL5FU point estimates were 263 L/h [231-295] 8 
and 175 L/h [87-263] in patients with wild-type DPYD genotype and homozygous mutations, respectively. 9 
Precision of these estimates was poor, and the effect of DPYD was not statistically significant, probably due to 10 
small number of mutations in the DPYD gene found in the studied population. IIV of CL5FU was correlated to 11 
MTHFR genotype with a ∆OFV of 8.98, but the covariate effect was not included in the model because of 12 
limitations with regard to mechanistic plausibility. Scaling CL5FUH2 with individual BSA reduced OFV by 6.76 13 
points with a marginal reduction in IIV (~2.1%). The estimate for BSA effect on CL5FUH2 (0.73 m-2) was close to 14 
that on CL5FU (0.79 m-2), therefore the BSA effect was included as a single parameter in the final model assuming 15 
a similarity in disposition kinetics between 5FU and 5FUH2. Using single parameter instead of two separate 16 
parameters provided no significant change in model fit (∆OFV = 0.35). Inclusion of cisplatin co-medication as a 17 
covariate upon slope parameter provided an improvement in model fit by reduction of 18.6 OFV points. Thus, the 18 
covariate relationships part of the PKPD model included effects of BSA on CL5FU and CL5FUH2, and of cisplatin 19 
comedication on slope.  20 
Simulated total WBC count over time 21 
Differences in simulated WBC count over time for 5FU monotherapy (5FUmono) and combination therapy 22 
(5FUcomb) are presented in fig. 3 (left panel). A higher degree of myelosuppression was observed for the typical 23 




































































total WBC count (fig. 3, right panel) showed a higher degree of myelosuppression for virtual subjects 1 
administered with the higher 5FU exposure in FOLFIRINOX regimen in comparison to de Gramont regimen.  2 
Discussion 3 
A semi-physiological PK/PD model of 5FU during continuous venous infusion was developed. Covariate effects 4 
including genetic variants of the main enzymes involved in 5FU PK and myelosuppression were tested. BSA was 5 
identified as a factor significantly influencing 5FU pharmacokinetics. Cisplatin co-administration was found to 6 
aggravate myelotoxicity. The current investigations are of particular value because they establish a link between 7 
5FU PK and myelosuppression in the same patients, where we were also able to characterize the PD interaction 8 
between 5FU and cisplatin. 9 
Approaches adapted to describe pharmacokinetics of 5FU have been nicely summarized by Deyme et al [14]. In 10 
most of the cases, a two-compartment model was found adequate to describe 5FU PK [3, 38, 39, 40], while some 11 
studies presented a one-compartment model [6, 41]. Most of these studies demonstrated a linear elimination [6, 12 
38, 41], whereas a nonlinear elimination was also observed occasionally [3, 40]. Both linear and nonlinear 13 
elimination kinetics were reported in one case [39]. In the current evaluation, a two-compartment model with 14 
linear elimination was the best to describe 5-FU PK. CL5FU of 249 L/h was comparable to the estimates obtained 15 
in similarly designed studies. Non-compartmental analysis with a 5-day continuous infusion estimated the CL5FU 16 
to be 257 L/h [42], while an estimate of 270 L/h was reported for a 3-day continuous infusion [43]. Population 17 
pharmacokinetic analysis performed by Etienne et al. presented an estimate of 235 L/h, where the data was 18 
described by a one-compartment model with first order elimination [7].  19 
BSA and C677T MTHFR genotype were significant covariates in our model. Despite the long-term use of BSA 20 
for 5FU dose individualization in clinical practice, existing studies provided conflicting results regarding 21 
suitability of BSA for prediction of 5FU exposure. Some studies did not report any significant relationship 22 
between BSA and 5FU exposure [7, 38, 44], while others considered BSA as the best predictor of CL5FU [5]. In a 23 
PKPD study, principally aiming to describe hematological toxicity under a combination regimen with 5FU, 24 




































































effects of either BSA [3] or body weight [44] on 5FU PK were confirmed in most population pharmacokinetic 1 
studies using nonlinear mixed-effect modelling. In the comparative covariate analysis, none of the indices 2 
representing body mass provided superiority over BSA regarding the improvement of model fit principally 3 
guided by reduction in OFV and % IIV. Patient’s gender was not found to influence CL5FU in the present study, 4 
which is consistent with a previous population pharmacokinetic analysis [7]. Gender effect on CL5FU observed in 5 
some studies [5, 41] might possibly be accounted for by differences in individual BSA. A considerably higher 6 
IIV of 145% was associated with Vc,5FU in comparison to previously reported values ranging from 19% to 114% 7 
[6, 38, 39, 41]. The CL5FUH2 (126 L/h) and VC,5FUH2 (91.9 L) estimates in our study were comparable to those 8 
reported by Mueller et al. [6]. An 18% higher CL5FUH2 in men was reported, but the gender influence is not 9 
supported by the present evaluation, probably because of the lower proportion of female patients in the studied 10 
population. It is worth mentioning that exploratory covariate analyses in small to medium sized studies are 11 
expected to result in different sets of covariates, especially in case the covariates demonstrate moderate to high 12 
correlation such as body size, age, sex, creatinine clearance etc.  13 
The effect of the MTHFR C677T mutation on CL5FU was found to be statistically significant. Population 14 
estimates for total clearance were 278 L/h (MTHFR 677CT or 677CC genotype) and 150 L/h (MTHFR 677TT 15 
genotype), but the genotype effect was not made part of the model due to lack of mechanistic plausibility as a 16 
predictor of 5FU PK. Published studies analysed this mutation primarily in relationship to 5FU efficacy and 17 
showed its favourable role in treatment response [46] and survival [47], considering the MTHFR genotype as an 18 
important predictor for the therapeutic effect of 5FU [48]. The common C677T polymorphism in the MTHFR 19 
gene results in a considerably lower enzyme activity [47] that probably increases intracellular folate 20 
concentrations, making tumors exhibiting mutated MTHFR genotypes more sensitive to cytotoxicity than wild-21 
type MTHFR tumors [49], if there are no differences in MTHFR genotype between tumor and somatic cells of the 22 
patient. It is difficult to deduce plausible mechanisms describing the influence of MTHFR on CL5FU based on the 23 
current knowledge on the metabolic pathways which provides a motivation to investigate this effect in further 24 




































































The semi-mechanistic myelosuppression model appropriately described the total WBC count over time after 5FU 1 
administration. Transit compartments accounted for a delay between drug administration and the observed effect. 2 
Self-renewal/mitosis in the proliferating cells compartment was dependent on the number of cells, a rate constant 3 
for cell division (kprol), and a feedback mechanism from the circulating cells (Circ0/Circ)γ which describes the 4 
rebound of cells as the proliferation rate is regulated by endogenous growth factors and cytokines [50]. An 5 
estimate of 6.86×109/L for baseline leukocyte count (Circ0) was in the expected range [22]. The Parameter 6 
estimates for γ (indicative of hematopoietic viability) were highly inconsistent across model runs; therefore, the 7 
value representative of a typical population was fixed according to the available literature [22]  in order to avoid 8 
an overshoot compared to Circ0. Myelosuppression was found to be significantly higher in patients receiving 9 
additional cisplatin (slope=2.82 L/mg) as compared to the patients undergoing monotherapy (slope=1.17 L/mg). 10 
In an attempt using a semi-physiological model to describe the relationship between the PK and the myelotoxicity 11 
contributed by respective components of the combination regimen comprised of 5FU, epirubicin and 12 
cyclophosphamide, the authors assumed negligible contribution by 5FU as it was not possible to estimate the 13 
effect contributed by 5FU and cyclophosphamide simultaneously [25]. The hypotheses underlying this strong 14 
assumption was a lower hematological toxicity observed with continuous infusions as compared to 5FU bolus 15 
administration [51], and a relatively stronger myelosuppression previously reported with epirubicin and 16 
cyclophosphamide in comparison to 5FU in rats [52]. When 5FU is investigated alone, the present results 17 
demonstrate a significant amount of myelosuppression related to 5FU continuous infusion with WBCnadir values 18 
of 2.26 (×109) and 4.29 (×109) in patients receiving 5FUcomb and 5FUmono regimens, respectively. Tnadir is typically 19 
expected between day 9 and day 14 with 5FU, however the simulated Tnadir in the present study was observed 20 
between day 22 to day 25 after start (=17 to 20 days after end) of infusion, which may possibly be attributed to 21 
the continuous nature of the infusion.  22 
A comparative evaluation of the theoretical contribution of a 5FU dose to myelosuppression expectedly predicted 23 
a more pronounced effect for the higher dose administered in the FOLFIRINOX regimen in comparison to de 24 
Gramont regimen. Although, hematological toxicities in case of combination based regimens are often additive in 25 
nature [53, 54, 55], a true prediction of the time course of myelosuppression under these therapeutic regimens 26 




































































differences in WBCnadir and Tnadir. Nevertheless, the simulations nicely show that just the FU component of even a 1 
single treatment course would put a considerable fraction of patients at risk for infections, as these doses are 2 
repeated every other week. Model based prediction of WBCnadir and Tnadir along with monitoring during the 3 
course of treatment can be imperative for suitable sampling schedules, assessment of the patient’s immune 4 
competence, and the expected consequence of additional treatment cycles [23]. Thus, it would be interesting to 5 
develop myelotoxicity models for 5-FU incorporating the effect of leucovorin in present regimens. Predictions 6 
may further be useful to identify patients or patient subgroups at a higher risk of toxicity. 7 
Conclusions  8 
A semi-physiological PKPD model of 5FU is presented. IIV in the CL5FU was partially explained by individual 9 
BSA. Frequent leukocyte count monitoring and model based predictions may be used to take the contribution of 10 
5-FU to myelosuppression into account, especially in case of polychemotherapy regimens. 11 
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Table 1: Patient characteristics (n = 30) 
Characteristics Value 
Sex (n male/ n female) 25/5 
Median age, years (range) 59.5 (37-73) 
Median Karnofsky performance status (range) 100% (100-100) 
Tumour primary site (n) 
    Oesophagus 
    Rectal 
    Colorectal 






Median body height, m (range) 1.75 (1.61-1.86) 
Median body weight, kg (range) 76 (46-111) 
Median BMI, kg/m2 (range) 24.2 (16.9-33.2) 
Median BSA, m2 (range) 1.95 (1.48-2.33) 
Median baseline laboratory values (range) 
    Haemoglobin (g/dL) 
    Platelet count (x103/uL) 
    Erythrocyte count (x106/uL) 
    Leukocyte count (x109/L) 
    Plasma albumin (g/dL) 
    Plasma ASAT (U/L) 
    Plasma ALAT (U/L) 
    Plasma -GT (U/L) 
    Plasma total bilirubin (mg/dL) 












Comedication with cisplatin (n) 14 
BSA = body surface area, BMI = body mass index, ASAT = aspartate aminotransferase,  
ALAT = alanine aminotransferase, -GT = gamma-glutamyl transferase 
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Table 2: Allele frequencies of polymorphisms in the DPYD gene found in patients 
Polymorphisms in 










frequency (%) *DPYD 
nomenclature 
Exon 
DPYD*9A 2 Cys29Arg (85T>C) 20 8 2 12/60 (20%) 
- 6 Met166Val (496A>G) 22 8 0 8/60 (13.33%) 
- 11 Glu412Glu (1236G>A) 29 1 0 1/60 (1.67%) 
DPYD*4 13 Ser534Asn (1601G>A) 29 1 0 1/60 (1.67%) 
DPYD*5 13 Ile543Val (1627A>G) 19 9 2 13/60 (21.67%) 
DPYD*6 18 Val732Ile (2194G>A) 28 2 0 2/60 (3.33%) 
DPYD = dihydropyrimidine dehydrogenase gene 
*Source of nomenclature:  Mcleod et al., 1998 [45] 
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Table 3: Bootstrap population pharmacokinetic and pharmacodynamic parameter estimates 
Parameter 
Population estimate IIV (%CV) 
Mean 95% CI RSE (%) Mean 95% CI RSE (%) 
5FU  
CL5FU (L/h)  249 224-276 6.36 23.0 12.3-30.1 43.1 
VC, 5FU (L) 5.56 2.41-9.87 42.0 145 75.3-204 57.0 
VP, 5FU (L) 28.5 13.3-59.3 81.5 - - - 
Q (L/h) 14.8 9.66-23.4 29.8 - - - 
BSA effect (m-2)a 0.77 0.44-1.14 28.0 - - - 
      AUC24,5FU (mg h/L)b 6.72 4.76-8.74 - - - - 
5FUH2  
Fm (%) 85 Fixed - - - - 
CL5FUH2 (L/h) 121 108-136 7.11 28.9 21.8-35.1 28.0 
VC, 5FUH2 (L) 96.7 74.8-119 14.37 59.6 30.7-96.3 76.8 
      AUC24,5FUH2 (mg h/L)b 12.2   7.12 - 19.2  - - -  
Total WBC count  
CIRC0 (×109/L) 6.86 6.38-7.37 4.50 16.4 8.29-22.8 52.0 
MTT (h)  281 224-344 13.1 - - - 
Slopecomb (L/mg) 2.82 1.53-3.77 27.2 - - - 
Slopemono (L/mg) 1.17 0.78-1.72 25.0 - - - 
γ 0.17 Fixed - - - - 
RUV (σ2)     
Proportional error 5FU  0.32 0.23-0.44 9.37 - - - 
Proportional error 5FUH2 0.14 0.10-0.18 9.61 - - - 
Proportional error Total WBC count 0.08 0.06-0.11 8.97 - - - 
CI = confidence interval, RSE = relative standard error, CL5FU = total clearance of 5FU, VC, 5FU =  5FU central volume of distribution, VP, 5FU = 
5FU peripheral volume of distribution, Q = intercompartmental clearance, BSA = body surface area, Fm = fraction of 5FU converted to 5FUH2, 
CL5FUH2 = clearance of 5FUH2, CIRC0 = baseline leukocyte count, MTT = mean transit time, Slopecomb = slope parameter for combination therapy 
with cisplatin, Slopemono = slope parameter for 5FU monotherapy, The “Slope” parameter represents the relationship between efffect and drug 
concentration into bone marrow (Edrug=slope×Cp), Cp = plasma concentration, IIV = interindividual variability,  RUV = residual unexplained 
variability, CV = coefficient of variation.   
a fractional change in CL per m2 difference from median BSA value, b calculated by obtaining time integral of drug concentrations using an 
additional compartment in NONMEM.  
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Figure legends 
Fig. 1: Schematic representation of PKPD model. Compartments with white background reflect the PK model 
describing 5FU and 5FUH2 plasma concentrations, while those with grey background reflect the PD model 
describing total WBC count over time. kprol: 1st order rate constant of proliferation, ktr: 1st order rate constant of 
transit, kcirc: 1st order rate constant of elimination of circulating cells, Circ0: baseline leucocyte count, γ: feedback 
parameter, Cp: 5FU plasma concentration, VC,5FU: 5FU central volume of distribution, VP,5FU: 5FU peripheral volume 
of distribution, CL5FU: 5FU total clearance, Q: intercompartmental clearance, Fm: fraction of 5FU converted to 
5FUH2, VC,5FUH2: 5FUH2 central volume of distribution, CL5FUH2: 5FUH2 clearance, drug effect: Edrug=slope ∙ Cp. 
Fig. 2: Visual predictive checks for 5FU (a) and 5FUH2 (b) plasma concentration data and total WBC count (c) over 
time. Continuous and dashed lines represent median, 2.5th and 97.5th percentiles of the observed data. Shaded areas 
are the 95% confidence interval for median, 2.5th and 97.5th percentiles of the simulated data. 5FU and 5FUH2 
plasma concentrations are presented on a log scale. 
Fig. 3: Left panel; Simulated total WBC count over time. Continuous line represents individuals receiving5FU 
monotherapy. Dashed line represents individuals receiving combination therapy with 5FU and cisplatin. Numbers 
represent corresponding WBCnadir values. Right panel: Simulated total WBC over time for effects attributable to a 
5FU dose as used in the FOLFIRINOX (400 mg/m2 bolus 5FU followed by 2400 mg/m2 over 46 h) versus the de 
Gramont regimens (300 mg/m2 i.v. bolus followed by 300 mg/m2 continuous infusion over 24 hrs): Continuous 
lines represent an individual receiving 5FU according to de Gramont regimen, while dashed lines represent an 
individual receiving the dose according to FOLFIRINOX regimen. Effects apply for a single treatment course, and 
those of the other components of the respective regimens are ignored in this figure. Numbers represent 
corresponding WBCnadir values. 
 





CL5FU × Fm 
Q 
CL5FUH2 





Mean Transit Time (MTT) = 4/ktr 
kcirc= ktr 








ktr ktr ktr 























































































0 10 20 30 40 50


























0 25 50 75 100


















Figure 3 Click here to access/download;Figure;Fig3.pdf
